IPO Traffic: Week Ending March 21, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Agile Therapeutics  (AGRX) RBC Capital Markets/ William Blair & Company     $69.00 n.a.
Alder BioPharmaceuticals  (ALDR) Credit Suisse/ Leerink Partners       $115.00 n.a.
GlobeImmune  (GBIM) Aegis Capital Corp.       $35.00 n.a.
Presbia PLC  (LENS) Jefferies       $90.00 n.a.
Signal Genetics (SGNL) Aegis Capital Corp 2.27 $10.00 $12.00 $24.99 n.a.
Tarena International (TEDU) Goldman Sachs (Asia)/ Credit Suisse 15.30 $8.00 $10.00 $137.70 n.a.
n.a. (not available)            
             
Postponed            
None            
             
             
Withdrawn            
Devon Midstream Partners, L.P.  (DVNM) BofA Merrill Lynch/ Barclays       $400.00 n.a.
Globoforce Ltd (THNX) J.P. Morgan/ Credit Suisse/ UBS Investment Bank/ Stifel 4.41 $16.00 $18.00 $75.00 2-Stars
             
New Terms            
2U, Inc. (TWOU) Goldman Sachs/ Credit Suisse 9.18 $11.00 $13.00 $110.10 3-Stars
Aerohive Networks (HIVE) Goldman Sachs/ BofA Merrill Lynch 7.50 $9.00 $11.00 $75.00 3-Stars
Aldeyra Therapeutics (ALDX) Aegis Capital Corp 2.28 $10.00 $12.00 $25.03 n.a.
CBS Outdoor Americas   (CBSO) Goldman Sachs/ BofA Merrill Lynch/ J.P. Morgan/ Morgan Stanley 20.00 $26.00 $28.00 $540.00 2-Stars
Energous (WATT) MDB Capital Group, LLC 4.00 $6.00 $6.00 $24.00 n.a.
Everyday Health  (EVDY) J.P. Morgan/ Credit Suisse/ Citigroup 7.15 $13.00 $15.00 $100.10 2-Stars
Rubicon Project (The) (RUBI) Morgan Stanley/ Goldman Sachs/ RBC Capital Markets, LLC 6.77 $15.00 $17.00 $108.34 3-Stars
SCYNEXIS (SCYX) RBC Capital Markets/ Canaccord Genuity 4.23 $12.00 $14.00 $55.00 n.a.
SunEdison Semiconductor  (SEMI) Deutsche Bank Securities/ Goldman Sachs/ Wells Fargo Securities $250.00 n.a.
Versartis  (VSAR) Morgan Stanley/ Citigroup 6.00 $19.00 $21.00 $120.00 3-Stars
             
IPOs Priced Lead Shares Amount Offer Close %
Week of March 17, 2014 Manager(s) Offered Raised Price 3/21/14 Change
Paylocity Holding  (PCTY) Deutsche Bank Securities/ BofA Merrill Lynch/ William Blair 7.05 $119.77 $17.00 $26.01 53.00%
Versartis  (VSAR) Morgan Stanley/ Citigroup 6.00 $126.00 $21.00 $31.37 49.38%
Akebia Therapeutics (AKBA) Morgan Stanley/ Credit Suisse/ UBS Investment Bank 5.88 $100.00 $17.00 $23.70 39.41%
Amber Road (AMBR) Stifel 7.39 $96.09 $13.00 $17.00 30.77%
MediWound Ltd.   (MDWD) Credit Suisse/ Jefferies/ BMO Capital Markets 5.00 $70.00 $14.00 $18.16 29.71%
Borderfree (BRDR) Credit Suisse/ RBC Capital Markets/ Pacific Crest Securities 5.00 $80.00 $16.00 $20.00 25.00%
Q2 Holdings (QTWO) J.P. Morgan/ Stifel 7.76 $100.89 $13.00 $16.13 24.08%
A10 Networks (ATEN) Morgan Stanley/ BofA Merrill Lynch/ J.P. Morgan Securities/ RBC Capital Markets 12.50 $187.50 $15.00 $16.21 8.07%
Ruthigen (RTGN) (u) Dawson James Securities 2.65 $19.21 $7.25 $7.25 0.00%
TPG Specialty Lending  (TSLX) J.P. Morgan/ BofA Merrill Lynch/ Goldman Sachs/ Citigroup/ Wells Fargo Securities/ Barclays 7.00 $112.00 $16.00 $16.00 0.00%

The IPO Buzz: Tech IPOs Take Off

Since the beginning of November 2013 through Friday, March 14, 2014, the average gain for all tech IPOs was 119.8 percent from their initial offering prices. But don’t get carried away in calling the sector a bubble. It isn’t here – yet.
 
Over the last three-plus months, the calendar has produced 92 IPOs, according to the U.S. Securities and Exchange Commission filings. Only four were technology IPOs. Nope – no tech bubble there.
 
Nevertheless, last Friday’s results helped the tech IPOs take off. Castlight Health (CSLT), a San Francisco-based provider of cloud-based software to manage healthcare costs, priced its IPO of 11.1 million shares on Thursday evening at $16 each. It closed on Friday at $39.80, UP 148.8 percent from its initial offering price.
 
Connections and Clouds
With this in mind, let’s take a look at this week’s IPO calendar and its tech-laden offerings:
 
  • A10 Networks (ATEN – proposed) is a San Jose, California-based provider of advanced application networking technologies. The company’s solutions enable enterprises, service providers, Web giants and government organizations to accelerate, secure and optimize the performance of their data center applications and networks. (For more information, please click here: A10 Networks)
  • Amber Road (AMBR – proposed) is an East Rutherford, New Jersey-based provider of cloud-based global trade management solutions to allow enterprises to automate import and export processes to flow across international borders. (For more information, please click here: Amber Road)
  • Borderfree (BRDR – proposed) is a New York City-based provider of international cross-border ecommerce. It operates a proprietary technology and services platform that enables U.S. retailers to transact business with consumers in more than 100 countries. (For more information, please click here: Borderfree)
  • Globoforce Ltd. (THNX – proposed) is a Dublin-based provider of a cloud-based, social recognition software solution that helps big corporations provide rewards for their employees. (For more information, please click here: Globoforce)
  • Paylocity Holding (PCTY – proposed) is an Arlington Heights, Illinois-based provider of cloud-based payroll and human capital management software solutions for medium-sized organizations. (For more information, please click here: Paylocity Holding)
  • Q2 Holdings (QTWO – proposed) is an Austin, Texas-based provider of secure cloud-based virtual banking solutions. (For more information, please click here: Q2 Holdings)
 
Designer Drugs
This brings us to the biotech/biopharma sector.
 
If you are looking for a bubble, this sector could be it. Since November, 29 of the 92 IPOs that have been priced were biotech/biopharma offerings. Their scorecard has been great. As of Friday’s close, 23 were in the winner’s circle, six were losers, and the average gain for all 29 was 71.9 percent. This week has three:
 
  • Akebia Therapeutics (AKBA – proposed) is a Cambridge, Massachusetts-based biopharmaceutical company focusing on therapeutics based on HIF biology and the commercialization of these products for patients with kidney disease. (For more information, please click here: Akebia Therapeutics)
  • MediWound (MDWD – proposed) is an Israeli-based biopharmaceutical company developing products to treat severe burns, chronic and other hard-to-heal wounds and connective tissue disorders. (For more information, please click here: MediWound Ltd.)
  • Versartis (VSAR – proposed) is a Redwood City, California-based biopharmaceutical company developing long-acting recombinant human growth hormone, VRS-317, for growth hormone deficiency, an orphan disease. (For more  information, please click here: Versartis)
 
Candy, Anyone?
There are another five deals on next week’s IPO calendar. The headliner is King Digital Entertainment plc (KING – proposed) and its Candy Crush Saga game.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.

IPO Traffic: Week Ending March 14, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Cerulean Pharma  (CERU) Leerink Partners       $75.00 n.a.
K2M Group Holdings (KTWO) Piper Jaffray/ Barclays/ Wells Fargo Securities     $100.00 n.a.
Leju Holdings Limited (LEJU) Credit Suisse/ J.P. Morgan       $200.00 n.a.
Lombard Medical (LMT) Jefferies/ Barclays       $80.00 n.a.
Papa Murphy’s Holdings (FRSH) Jefferies/ Baird/ Wells Fargo Securities     $70.00 n.a.
Paycom Software (PAYC) Barclays/ J.P. Morgan       $100.00 n.a.
Phibro Animal Health (PAHC) BofA Merrill Lynch/ Morgan Stanley/ Barclays     $230.00 n.a.
Synchrony Financial   (SYF) Goldman Sachs/ J.P. Morgan/ Citigroup/ Morgan Stanley/ Barclays/ BofA Merrill Lynch/ Credit Suisse/ Deutsche Bank Securities $100.00 n.a.
Trinseo S.A.  (TSE) Goldman Sachs/ Deutsche Bank Securities/ Citigroup/ Morgan Stanley/ Barclays/ BofA Merrill Lynch/ HSBC/ Jefferies/ Mizuho Securities/ Scotiabank/ SMBC Nikko/ Wells Fargo Securities $200.00 n.a.
TriVascular Technologies  (TRIV) J.P. Morgan/ Credit Suisse       $100.00 n.a.
Vital Therapies (VTL) BofA Merrill Lynch/ Credit Suisse       $100.00 n.a.
Weibo   (TBA) Goldman Sachs (Asia)/ Credit Suisse       $500.00 n.a.
Zoe’s Kitchen  (ZOES) Jefferies/ Piper Jaffray/ Baird       $80.50 n.a.
n.a. (not available)            
             
Postponed            
Diamond S Shipping Group (DSG) Jefferies/ BofA Merrill Lynch 14.00 $14.00 $16.00 $210.00 2-Stars
             
Withdrawn            
Waypoint Homes Realty Trust  (WAY) Citigroup/Jefferies       $100.00 1-Star
             
New Terms            
A10 Networks (ATEN) Morgan Stanley/ BofA Merrill Lynch/ J.P. Morgan Securities/ RBC Capital Markets 12.50 $13.00 $15.00 $175.00 3-Stars
Applied Genetic Technologies (AGTC) BMO Capital Markets/ Wedbush PacGrow Life Sciences 3.75 $13.00 $15.00 $52.51 n.a.
Bluerock Residential Growth REIT (BRG) Wunderlich Securities 3.33 $15.00 $15.00 $50.00 1-Star
Borderfree (BRDR) Credit Suisse/ RBC Capital Markets/ Pacific Crest Securities 5.00 $14.00 $16.00 $75.00 3-Stars
Castlight Health (CSLT) Goldman Sachs/ Morgan Stanley 11.10 $13.00 $15.00 $155.40 3-Stars
Globoforce Ltd (THNX) J.P. Morgan/ Credit Suisse/ UBS Investment Bank/ Stifel 4.41 $16.00 $18.00 $75.00 3-Stars
King Digital Entertainment plc   (KING) J.P. Morgan/ Credit Suisse/ BofA Merrill Lynch/ Barclays/ Deutsche Bank/ RBC Capital Markets 22.20 $21.00 $24.00 $499.50 3-Stars
Nord Anglia Education (NORD) Credit Suisse/ Goldman Sachs/ J.P. Morgan 19.00 $15.00 $17.00 $304.00 2-Stars
Ruthigen (RTGN) Dawson James Securities 2.20 $7.25 $9.25 $18.15 1-Star
Square 1 Financial  (SQBK) Sandler ONeill & Partners/ Keefe, Bruyette & Woods (A Stifel Company) 5.88 $15.00 $17.00 $94.10 n.a.
TriNet Group   (TNET) J.P. Morgan/ Morgan Stanley/ Deutsche Bank Securities 15.00 $15.00 $17.00 $240.00 3-Stars
Versartis  (VSAR) Morgan Stanley/ Citigroup 4.60 $16.00 $19.00 $80.50 2-Stars
             
IPOs Priced Lead Shares Amount Offer Close %
Week of March 10, 2014 Manager(s) Offered Raised Price 3/14/14 Change
Castlight Health (CSLT) Goldman Sachs/ Morgan Stanley 11.10 $177.60 $16.00 $39.80 148.75%
Achaogen (AKAO) Credit Suisse/ Cowen and Company 6.00 $72.00 $12.00 $16.16 34.67%
Dipexium Pharmaceuticals  (DPRX) Oppenheimer & Co. 2.75 $33.00 $12.00 $13.40 11.67%
Galmed Pharmaceuticals Ltd.  (GLMD) Maxim Group LLC 2.84 $38.30 $13.50 $14.65 8.52%

The IPO Buzz: Tech IPOs on a Joyride

Castlight Health (CSLT – proposed), a San Francisco-based provider of cloud-based software to manage healthcare costs, tops this week’s IPO calendar.
 
Next week has Amber Road (AMBR – proposed), an East Rutherford, New Jersey-based provider of cloud-based global trade management solutions; Paylocity Holding (PCTY – proposed), an Arlington Heights, Illinois-based provider of cloud-based payroll and human capital management software solutions; and Q2 Holdings (QTWO – proposed), an Austin, Texas-based provider of secure cloud-based virtual banking solutions.
 
Two tech companies filed plans to go public last week:
Five9
 (FIVN – proposed), a San Ramon, California-based provider of cloud software for contact centers, and Opower
 (OPWR – proposed), an Arlington, Virginia-based provider of cloud-based software for the utility industry.
 
Up, Up and Away
Since the Labor Day break in September, the IPO technology sector has been on fire. From Sept. 3, 2013, through March 7, 2014, the technology sector has priced 18 IPOs, according to the U.S. Securities and Exchange Commission filings. Seventeen were in the winner’s circle, one wasn’t, and the average gain for all 18 was 123.1 percent from their initial offering price. Additionally, 10 were up 100 percent or more.
 
The best performer was FireEye (FEYE), a Milpitas, California-based provider of virtual machine-based IT security software. On Sept. 19, 2013, the company priced its IPO at $20 per share. It closed its opening day at $36, and closed Friday at $81.64, UP 305.2 percent from its initial offering price.
 
Let’s take a look at the recent past. Last week’s calendar of Feb. 24, produced:
 
COUPONS.com (COUP), a Mountain View, California-based provider of digital coupons, priced its IPO of 10.5 million shares at $16 each, UP from 10 million shares at $13 to $14 each on Thursday evening, March 7. It closed Friday at $30, UP 87.5 percent from its initial offering price.
 
The previous week’s calendar of Feb. 17, produced:
Varonis Systems (VRNS), a New York City-based provider of a software platform that lets companies manage and protect their unstructured data, priced its IPO of 4.8 million shares at $22 each, UP from 4.8 million shares at $17 to $19 each on Thursday evening, Feb. 27. It closed Friday, Feb. 28, at $44, UP 100 percent from its initial offering price, and closed Friday, March 7, at $53.48, UP 143.1 percent from its offering price.
 
That brings us to this week and its IPO calendar. All told, there are five deals looking to raise about $450 million. Most of the dollar volume comes from two offerings. They are Castlight Health and Diamond S Shipping (DSG – proposed).
 
Health, Wealth and Oil
Castlight Health is a provider of cloud-based software that enables enterprises to gain control over their healthcare costs. Castlight’s Enterprise Healthcare Cloud allows customers to provide personalized, actionable information to their employees, implementing technology-enabled benefit designs and integrating disparate systems and applications. Formed in 2009, Castlight Health has about 287 employees.
 
Underwriters plan to offer 11.1 million shares of Castlght Health at $9 to $11 each to raise about $111 million. The IPO is expected to be priced Thursday evening and trade Friday morning on the New York Stock Exchange. The joint-lead managers are: Goldman Sachs and Morgan Stanley. The co-managers are: Allen & Company, Stifel, Canaccord Genuity and Raymond James.
 
Diamond S Shipping Group is a Greenwich, Connecticut-based provider of seaborne transportation of refined petroleum and other products in the international shipping markets. The company operates a fleet 33 MR product tankers. Thirty are with 30 under-time charters; the remaining three operate in the spot market. Formed in 2007, Diamond S Shipping has about 29 employees.
 
Underwriters plan to offer 14 million shares of Diamond S Shipping at $14 to $16 each to raise about $210 million. The IPO is expected to be priced Tuesday evening and trade Wednesday morning on the New York Stock Exchange. The joint-lead managers are: Jefferies and BofA Merrill Lynch. The co-managers are: DNB Markets, HSBC, SEB, Global Hunter Securities, Fearnley Securities and Stifel.
 
There are only five deals on next week’s IPO calendar. Three cloud-based companies are on tap for the week of March 17, which happens to be St. Patrick’s Day. There’s still a lot of time to add more names early this week.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.

IPO Traffic: Week Ending March 7, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
Adamas Pharmaceuticals (ADMS) Credit Suisse/ Piper Jaffray       $69.00 n.a.
Biomet Group  (BMET) BofA Merrill Lynch/ Goldman Sachs/ J.P. Morgan     $100.00 n.a.
Corium International (CORI) Jefferies/ Leerink Partners       $50.00 n.a.
Dorian LPG  (LPG) J.P. Morgan/ UBS Investment Bank       $287.50 n.a.
Five9 (FIVN) J.P. Morgan/ Barclays/ BofA Merrill Lynch     $100.00 n.a.
iKang Healthcare Group (KANG) BofA Merrill Lynch/ UBS Investment Bank     $150.00 n.a.
Moelis  (MC) Goldman Sachs/ Morgan Stanley/ Moelis & Company   $100.00 n.a.
Opower (OPWR) Morgan Stanley/ Goldman Sachs       $100.00 n.a.
Quotient (QTNT) UBS Investment Bank/ Baird/ Cowen        $75.00 n.a.
Sportsmans Warehouse Holdings  (SPWH) Credit Suisse/ Goldman Sachs       $201.00 n.a.
n.a. (not available)            
             
Postponed            
None            
             
Withdrawn            
None            
             
New Terms            
Akebia Therapeutics (AKBA) Morgan Stanley/ Credit Suisse/ UBS Investment Bank 4.90 $14.00 $17.00 $75.95 n.a.
Amber Road (AMBR) Stifel 6.52 $10.50 $12.50 $75.01 n.a.
Applied Genetic Technologies (AGTC) BMO Capital Markets/ Wedbush PacGrow Life Sciences   $70.00 n.a.
Castlight Health   (CSLT) Goldman Sachs/ Morgan Stanley 11.10 $9.00 $11.00 $111.00 3-Stars
City Office REIT  (CIO) Janney Montgomery Scott/ Wunderlich Securities/ Oppenheimer $115.00 n.a.
MediWound Ltd.   (MDWD) Credit Suisse/ Jefferies/ BMO Capital Markets 5.00 $14.00 $16.00 $75.00 n.a.
Paylocity Holding  (PCTY) Deutsche Bank Securities/ BofA Merrill Lynch/ William Blair 6.67 $14.00 $16.00 $100.05 n.a.
Q2 Holdings (QTWO) J.P. Morgan/ Stifel 7.76 $11.00 $13.00 $93.13 n.a.
Versartis  (VSAR) Morgan Stanley/ Citigroup       $80.00 n.a.
             
IPOs Priced Lead Shares Amount Offer Close %
Week of March 3, 2014 Manager(s) Offered Raised Price 3/7/14 Change
COUPONS.com (  COUP) Goldman Sachs/ Allen & Company/ BofA Merrill Lynch/ RBC Capital Markets 10.50 $168.00 $16.00 $30.00 87.50%
Aquinox Pharmaceuticals  (AQXP) Jefferies/ Cowen and Company 4.20 $46.20 $11.00 $11.95 8.64%
Recro Pharma  (REPH) Aegis Capital Corp 3.75 $30.00 $8.00 $8.30 3.75%
TriplePoint Venture Growth BDC (TPVG) Morgan Stanley/ Wells Fargo Securities/ Goldman Sachs/ Credit Suisse/ UBS Investment Bank 8.32 $124.83 $15.00 $15.55 3.67%

Traffic Test

Lead Manager/ # of Price Range Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
58.com (WUBA) Morgan Stanley/ Credit Suisse/ Citigroup $150.00 n.a.
Apparel Holding (VNCE) Goldman Sachs/ Baird $200.00 n.a.
Biocept(BIOC ) Aegis Capital $23.00 n.a.
CatchMark Timber Trust(CTT) Raymond James $172.50 n.a.
Chrysler Group (tba) J.P. Morgan $100.00 n.a.
Devon Midstream Partners, L.P. (DVNM) BofA Merrill Lynch/ Barclays $400.00 n.a.
Evogene Ltd. (EVGN) Credit Suisse/ Deutsche Bank Securities $60.00 n.a.
Marcus & Millichap(MMI) Citigroup/ Goldman Sachs $103.50 n.a.
Relypsa (tba) Morgan Stanley/ BofA Merrill Lynch $126.50 n.a.
Southeastern Grocers(SEG) Citigroup/ Credit Suisse/ Deutsche Bank Securities/ William Blair/ Wells Fargo Securities $500.00 n.a.
n.a. (not available)
Postponed
None
Withdrawn
None
New Terms
ADMA Biologics (tba) Oppenheimer & Co. 2.67 $8.50 $9.50 $24.00 n.a.
Brixmor Property Group (BRX) BofA Merrill Lynch/ Citigroup/ J.P. Morgan/ Wells Fargo Securities/ Barclays/ Deutsche Bank Securities/ RBC Capital Markets/ UBS Investment Bank $100.00 n.a.
Cherry Hill Mortgage Investment (CHMI) Barclays/ Morgan Stanley/ Citigroup/ UBS Investment Bank 6.50 $20.00 $20.00 $130.00 n.a.
Energy & Exploration Partners (ENXP) Citigroup $270.00 n.a.
OCI Partners LP. (OCIP) BofA Merrill Lynch/ Barclays/ Citigroup 17.50 $19.00 $21.00 $350.00 n.a.
Ophthotech(OPHT) Morgan Stanley/ J.P. Morgan 7.60 $19.00 $20.00 $148.20 3-Stars
Plains GP Holdings, L.P.(PAGP) Barclays/ Goldman Sachs/ J.P. Morgan/ BofA Merrill Lynch/ Citigroup/ UBS Investment Bank/ Wells Fargo Securities $1,000.00 n.a.
Potbelly Corporation (PBPB) BofA Merrill Lynch/ Goldman, Sachs 7.50 $9.00 $11.00 $75.00 3-Stars
QTS Realty Trust(QTS) Goldman, Sachs/ Jefferies 12.50 $27.00 $30.00 $356.25 n.a.
SFX Entertainment(SFXE) UBS Investment Bank/ Jefferies/ Deutsche Bank Securitie 16.67 $11.00 $13.00 $200.00 n.a.
Western Refining Logistics, LP(WNRL) BofA Merrill Lynch/ Barclays/ Goldman Sachs/ Wells Fargo Securities $287.50 n.a.
n.a. (not available)
tba (to be announced)
IPOs Priced Lead Shares Amount Offer Close %
Week of Sept. 23, 2013 Manager(s) Offered Raised Price 9/27/13 Change
Foundation Medicine (FMI) Goldman, Sachs/ J.P. Morgan 5.89 $106.00 $18.00 $35.65 98.06%
Montage Technology Group (MONT) Deutsche Bank Securities/ Barclays/ Stifel 7.10 $71.00 $10.00 $15.15 51.50%
RingCentral (RNG) Goldman, Sachs/ J.P. Morgan/ BofA Merrill Lynch 7.50 $97.50 $13.00 $18.20 40.00%
Ophthotech(OPHT) Morgan Stanley/ J.P. Morgan 7.60 $167.20 $22.00 $29.18 32.64%
Enzymotec (ENZY) BofA Merrill Lynch/ Jefferies 4.41 $61.77 $14.00 $18.16 29.71%
Covisint (COVS) Credit Suisse/ Pacific Crest Securities 6.40 $64.00 $10.00 $12.63 26.30%
Premier (PINC) J.P. Morgan/ BofA Merrill Lynch/ Wells Fargo Securities 28.15 $760.10 $27.00 $31.69 17.37%
Pattern Energy Group (PEGI) BMO Capital Markets/ RBC Capital Markets/ Morgan Stanley 16.00 $352.00 $22.00 $23.27 5.77%
Applied Optoelectronics(AAOI) Raymond James/ Piper Jaffray 3.60 $36.00 $10.00 $10.10 1.00%
Evoke Pharma (EVOK) Aegis Capital Corp. 2.10 $25.20 $12.00 $12.03 0.25%
Capitala Finance (CPTA) Deutsche Bank Securities/ UBS Investment Bank/ Barclays 4.00 $80.00 $20.00 $19.05 -4.75%
Violin Memory (VMEM) J.P. Morgan/ Deutsche Bank Securities/ BofA Merrill Lynch 18.00 $162.00 $9.00 $7.02 -22.00%
Posted in Uncategorized

The IPO Buzz: Tech IPOs Light Up the Sky

There’s more to the tech IPO world. At last count, well over a dozen tech IPOs were in the pipeline waiting for their turn on the calendar. This could usher in the “New Age of Tech IPOs.”
 
First Tech IPO of 2014
Varonis Systems (VRNS), a New York City-based provider of a software platform that lets companies manage and protect their unstructured data, priced its IPO of 4.8 million shares at $22 each on Thursday evening, Feb. 27, 2014. It closed its opening-day at $44 per share, UP 100 percent from its initial public offering price.
 
Last Tech IPO of 2013
Nimble Storage (NMBL), a San Jose, California-based provider of information technology, hardware and software products for data storage, priced its IPO of 8 million shares at $21 each on Thursday evening, Dec. 12, 2013. It closed its opening day at $33.93, UP 61.6 percent from its initial offering price. On Friday, Feb. 28, 2014, Nimble closed at $48.10 per share, UP 128.6 percent from its initial public offering price.
 
This Week’s Tech IPO
COUPONS.com (COUP – proposed), a Mountain View, California-based provider of digital coupons, including online printable, social media, mobile and loyalty card promotions for more than 2,000 brands from more than 700 consumer package-goods companies, grocery, drug and mass merchandise retailers. For the three-month period ended Dec. 31, 2013, COUPONS.com reported net income of $1.5 million on revenues of $52.6 million, compared with a net loss of $9.1 million on revenues of $35.8 million for the same period a year ago. Founded in 1998, the company has about 469 employees.
 
Underwriters plan to offer 10 million shares of COUPONS.com at $12 to $14 each to raise about $130 million. The IPO is expected to be priced Thursday evening and trade Friday morning on the New York Stock Exchange. The joint-lead managers are Goldman Sachs, Allen & Company, BofA Merrill Lynch and RBC Capital Markets.
 
The Tech Watch List
There are about 15 IPOs falling under the technology sector, according to the U.S. Securities and Exchange Commission filings. Among them are:
  • Aerohive Holdings (HIVE – proposed) is a Sunnyvale, California-based provider of cloud-based WiFi and routing products.
  • Amber Road (AMBR – proposed) is an East Rutherford, New Jersey-based provider of cloud-based global trade management solutions.
  • Borderfree (BRDR – proposed) is a New York City-based e-commerce provider of a technology and services platform that enables U.S. retailers to transact business in more than 100 countries and territories.
  • JD.COM (no proposed symbol available) believes it is the largest online direct sales company in China. The company filed plans to raise US$1.5 billion.
IPO Lightning
Under the April 2012 JOBS Act, a company can file to go public and be on the IPO calendar from within days to a few weeks.
This week includes an example of the lightning speed from the pipeline to the calendar:
 
Aquinox Pharmaceuticals (AQXP – proposed) filed to go public, planning to raise $57.5 million, on Jan. 28, 2014.
 
Fast forward: Friday, Feb. 28, Aquinox filed an amendment announcing its proposed pricing terms. The offering was on the IPO calendar expecting to be priced the following Thursday evening, March 6. That’s just five business days later.
 
Aquinox Pharmaceuticals is a Vancouver, British Columbia-based clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation and cancer. The Canadian company’s leading drug candidate, AQX-1125, is being investigated in two Phase 2 clinical trials – one to evaluate its effectiveness in treating chronic obstructive pulmonary disease, also known as COPD, and another to investigate its ability to reduce pain and urinary symptoms in bladder pain syndrome, also known as interstitial cystitis, a condition that mostly affects women. Founded in 2003, Aquinox has about 12 employees.
 
Underwriters plan to offer 3.7 million shares of Aquinox Pharmaceuticals at $10 to $12 each to raise about $40.7 million. The IPO is expected to be priced Thursday evening and trade Friday morning on the NASDAQ Global Market. The joint-lead managers are Jefferies and Cowen. The co-manager is Canaccord Genuity.
 
Looking into next week, the calendar has three IPOs. But more names could land on the IPO launching pad by the time that Monday, March 10, rolls around.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.

IPO Traffic: Week Ending Feb. 28, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
ETRE REIT (ECAV) Sandler O’Neill + Partners, L.P.       $53.00 n.a.
Everyday Health  (EVDY) J.P. Morgan/ Credit Suisse/ Citigroup       $115.00 n.a.
Grubhub   (GRUB) Citigroup/ Morgan Stanley       $100.00 n.a.
Radius Health  (RDUS) Jefferies/ Cowen and Company       $86.25 n.a.
SCYNEXIS (SCYX) RBC Capital Markets/ Canaccord Genuity     $55.00 n.a.
Tarena International   (TEDU) Goldman Sachs (Asia) L.L.C./ Credit Suisse     $100.00 n.a.
n.a. (not available)            
             
Postponed            
None            
             
Withdrawn            
None            
             
             
New Terms            
1347 Property Insurance Holdings (PIH) Aegis Capital Corp 2.27 $10.00 $12.00 $25.00 1-Star
Achaogen (AKAO) Credit Suisse/ Cowen and Company 5.00 $12.00 $14.00 $65.00 1-Star
Aquinox Pharmaceuticals  (AQXP) Jefferies/ Cowen and Company 3.70 $10.00 $12.00 $40.70 1-Star
COUPONS.com (  COUP) Goldman Sachs/ Allen & Company/ BofA Merrill Lynch/ RBC Capital Markets 10.00 $12.00 $14.00 $130.00 3-Stars
Diamond S Shipping Group  (DSG) Jefferies/ BofA Merrill Lynch 14.00 $14.00 $16.00 $210.00 2-Stars
Dipexium Pharmaceuticals  (DPRX) Oppenheimer & Co. 2.31 $12.00 $14.00 $30.00 1-Star
Galmed Pharmaceuticals Ltd.  (GLMD) Maxim Group LLC 2.35 $12.00 $14.00 $30.55 n.a.
La Quinta Holdings  (LQ) J.P. Morgan/ Morgan Stanley       $650.00 n.a.
n.a. (not available)            
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Feb. 24, 2014 Manager(s) Offered Raised Price 2/28/14 Change
Varonis Systems (VRNS) Morgan Stanley/ Barclays Capital/ Jefferies 4.80 $105.60 $22.00 $44.00 100.00%
Lumenis Ltd (LMNS) Goldman Sachs/ Credit Suisse/ Jefferies 6.25 $75.00 $12.00 $12.20 1.67%

The IPO Buzz: IPO Jockeys and Litmus Tests

The advice around the betting window at the IPO Downs is: “If you don’t know the horse, bet on the jockey.” That applies to this week’s first IPO.
 
The Jockey
Lumenis (LMNS – proposed) is an Israeli-based provider of medical and aesthetic lasers and light-based technology. Lumenis plans to price 6.25 million shares at $15 to $17 each on Wednesday evening to trade Thursday morning on the NASDAQ Global Market. Founded in 1991, Lumenis has about 1,061 employees. For the year ended Dec. 31, 2013, Lumenis reported net income of $17.4 million on revenues of $265.4 million. The joint-lead managers are: Goldman Sachs, Credit Suisse and Jefferies. The co-manager is: Wells Fargo Securities.
 
So far, so good.
 
But the last three medical equipment companies to go public stumbled on their first day on the IPO racetrack. (Note: All were priced over the last two weeks.) They were:
  • Amedica (AMDA) is a Salt Lake City-based provider of silicon nitride ceramic technologies for spine and joint implants for the orthopedic device market. Amedica priced its IPO of 3.5 million shares at $5.75 each on Feb. 12, cut from 3.2 million shares at $10 to $12 each. The IPO closed its opening day at $5.39, DOWN 6.3 percent from its initial offering price.
  • Inogen (INGN) is a Goleta, California-based provider of portable oxygen concentrators. Inogen priced its IPO of 4.4 million shares at $16 each on Feb. 13, on the low end of its price range of $16 to $18 per share. The IPO closed its opening day at $15.15, DOWN 5.31 percent from its initial offering price.
  • Semler Scientific (SMLR) is a Portland, Oregon-based provider of patented products that identify the risk profile of medical patients. Semler Scientific priced its IPO of 1.4 million shares at $7 each on Feb. 20, cut from 1.2 million shares at $12 to $14 each. The IPO closed its opening day at $6.99, DOWN 0.41 percent from its initial offering price.
Opening-day results like these won’t make people run to the betting window with wads of cash.
 
The Goldman Rule
Now let’s take a look at Lumenis’ jockey – or bookrunner. It is Goldman Sachs, the first name on the cover page of the prospectus.
 
Labor Day was just six months ago. Since then, 126 IPOs have been priced, according to the U.S. Securities and Exchange Commission files.(Note: This excludes unit offerings consisting of common stock and warrants, closed-end investment companies and American Depositary Shares being offered for the first time in the U.S. capital markets that represent shares already traded on the companies’ own national stock exchanges.)
 
Goldman Sachs was the bookrunner for 17 IPOs. Their opening-day results: 13 winners, three losers and one unchanged. Average gain for all 17 was 39.7 percent.
 
The rest of Wall Street: 73 winners, 29 losers and seven unchanged. Average gain for all 109 was 19.6 percent.
 
Put more simply, Goldman Sachs outperformed the Street by a ratio of about 2 to 1 in terms of average gain.
 
The Litmus Test
The buzz in recent weeks has centered around this theme: Technology IPOs are coming back in style. The second deal on this week’s IPO calendar is from the tech sector. It’s seen as the litmus test on how tech IPOs might fare in the near future.
 
Varonis Systems (VRNS – proposed) is a New York City-based provider of a software platform that lets companies manage and protect their unstructured data. This includes the user’s spreadsheets, word-processing documents, presentations, audio files, video files, emails, text messages and any other data created by employees. This data often contains the user’s financial information, product plans, strategic initiatives, intellectual property and numerous other forms of vital information.
 
Varonis plans to price 4.8 million shares at $17 to $19 each on Thursday evening to trade Friday morning on the NASDAQ Global Market. Founded in 2004, the company has about 573 employees. From the year ended Dec. 31, 2013, Varonis reported a net loss of $7.5 million on revenues of $74.6 million. The joint-lead managers are: Morgan Stanley, Barclays Capital, Jefferies and RBC Capital Markets. The co-manager is: Needham.
 
It has been over two months since a tech IPO was priced.
 
Nimble Storage (NMBL) is a San Jose, California-based provider of a flash-optimized hybrid storage platform. Nimble priced its IPO of 8 million shares at $21 each on Dec. 12, 2013. The price was increased from its original filing of $16 to $18 per share. The IPO closed its opening day at $33.93, UP 61.6 percent from its initial offering price.
 
The bookrunner: Goldman Sachs.
 
Tech Rush and Candy Crush
For the last several weeks, the financial press has been reporting that exotic technology companies have filed confidential plans to go public under the JOBS Act. Among those mentioned were: GoPro, a San Mateo, California-based brand of high-definition personal cameras used in extreme action video photography, and PubMatic, a Redwood City, California-based online advertising company.
 
On a formal note, the SEC has jumped into the act. Last week, the SEC reported some noteworthy filings by technology IPOs. Among them were: 2U (TWOU – proposed) a Landover, Maryland-based provider of cloud-based software-as-a-service solutions that enable nonprofit colleges and universities to deliver education to students anywhere; A10 Networks (ATEN – proposed) a San Jose, California-based provider of advanced application networking technologies that let companies, service providers, Web giants and government organizations accelerate, secure and optimize the performance of their data center applications and networks, and King Digital Entertainment (KING – proposed), the Dublin, Ireland-based maker of Candy Crush Saga, a popular (some say, addictive)interactive smartphone game.
 
Interestingly enough, not one technology IPO has made its public debut this year – until this week. The whole world is watching to see how the Varonis deal works out. If it pops, then technology will be “in.”
 
Looking into next week, the calendar has one IPO. But more names could pop onto the IPO launching pad by the time that Monday, March 3, rolls around.
 
Stay tuned.
 
Disclosure: Neither the author nor anyone else on the IPOScoop.com staff has a position in any stocks mentioned, nor do we trade or invest in IPOs. The author and IPOScoop.com staff do not issue advice, recommendations or opinions.
 
 

IPO Traffic: Week Ending Feb. 21, 2014

  Lead Manager/ # of Price Range   Dollar SCOOP
New Filings (Proposed Symbol) Joint-Lead Managers Shares Low High Volume Ratings
2U, Inc. (TWOU) Goldman Sachs/ Credit Suisse       $100.00 n.a.
A10 Networks (ATEN) Morgan Stanley/ BofA Merrill Lynch/ J.P. Morgan Securities/ RBC Capital Markets $100.00 n.a.
Borderfree (BRDR) Credit Suisse/ RBC Capital Markets/ Pacific Crest Securities   $86.25 n.a.
King Digital Entertainment plc   (KING) J.P. Morgan/ Credit Suisse/ BofA Merrill Lynch/ Barclays/ Deutsche Bank/ RBC Capital Markets $500.00 n.a.
Nord Anglia Education (NORD) Credit Suisse/ Goldman Sachs/ J.P. Morgan     $300.00 n.a.
Versartis  (TBA) Morgan Stanley/ Citigroup       $80.00 n.a.
n.a. (not available)            
             
Postponed            
Sundance Energy Australia Limited (SNDE) Wells Fargo Securities/ Canaccord Genuity/ UBS Investment Bank 7.75 $16.50 $18.50 $135.63 N/C
N/C – The ordinary shares are listed on the Australian Securities Exchange           
             
Withdrawn            
None            
             
New Terms            
CBS Outdoor Americas   (CBSO) Goldman Sachs/ BofA Merrill Lynch/ J.P. Morgan/ Morgan Stanley $100.00 n.a.
Semler Scientific (SMLR) Aegis Capital Corp 1.18 $7.50 $9.50 $10.03 n.a.
Varonis Systems (VRNS) Morgan Stanley/ Barclays Capital/ Jefferies 4.80 $17.00 $19.00 $86.40 2-Stars
n.a. (not available)            
             
IPOs Priced Lead Shares Amount Offer Close %
Week of Feb. 17, 2014 Manager(s) Offered Raised Price 2/21/14 Change
Semler Scientific (SMLR) Aegis Capital Corp 1.43 $10.01 $7.00 $6.99 -0.14%